Iterum Therapeutics (ITRM)
1.18
-0.05 (-4.07%)
At close: Apr 01, 2025, 3:59 PM
1.18
0.07%
After-hours: Apr 01, 2025, 05:27 PM EDT
Company Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics
| Country | IE |
| IPO Date | May 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Corey N. Fishman |
Contact Details
Address: Fitzwilliam Court Dublin, IE | |
| Website | https://www.iterumtx.com |
Stock Details
| Ticker Symbol | ITRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659323 |
| CUSIP Number | G6333L101 |
| ISIN Number | IE000TTOOBX0 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Corey N. Fishman | President, Chief Executive Officer & Director |
| Judith M. Matthews | Chief Financial Officer |
| Dr. Michael W. Dunne M.D. | Strategic Advisor & Director |
| Dr. Steven I. Aronin M.D. | Senior Vice President & Head of Clinical Development |
| Louise Barrett | Senior Vice President of Legal Affairs & Secretary |
| Tom Loughman Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | 3 | Filing |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | 8-K | Current Report |
| Feb 07, 2025 | S-3 | Filing |
| Feb 07, 2025 | 10-K | Annual Report |
| Feb 07, 2025 | 8-K | Current Report |
| Jan 23, 2025 | 4 | Filing |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 10, 2024 | 424B5 | Filing |